Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Current status of antiplatelet agents to prevent stroke.

Field TS, Benavente OR.

Curr Neurol Neurosci Rep. 2011 Feb;11(1):6-14. doi: 10.1007/s11910-010-0162-y. Review.

2.

Antiplatelet agents for stroke prevention.

Yip S, Benavente O.

Neurotherapeutics. 2011 Jul;8(3):475-87. doi: 10.1007/s13311-011-0060-2. Review.

3.

Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.

Jamieson DG, Parekh A, Ezekowitz MD.

J Cardiovasc Pharmacol Ther. 2005 Sep;10(3):153-61. Review.

PMID:
16211203
4.

Combination antiplatelet agents for secondary prevention of ischemic stroke.

Vande Griend JP, Saseen JJ.

Pharmacotherapy. 2008 Oct;28(10):1233-42. doi: 10.1592/phco.28.10.1233. Review.

PMID:
18823219
5.
6.

Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].

Kirshner HS.

Int J Clin Pract. 2007 Oct;61(10):1739-48. Review. Erratum in: Int J Clin Pract. 2007 Nov;61(11):1957.

7.

Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.

Malloy RJ, Kanaan AO, Silva MA, Donovan JL.

Clin Ther. 2013 Oct;35(10):1490-1500.e7. doi: 10.1016/j.clinthera.2013.09.004.

PMID:
24139421
9.

Antiplatelet agents and randomized trials.

Diener HC.

Rev Neurol Dis. 2007 Fall;4(4):177-83. Review.

PMID:
18195669
11.

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.

De Schryver EL, Algra A, van Gijn J.

Cochrane Database Syst Rev. 2003;(1):CD001820. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD001820.

PMID:
12535415
12.

Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.

Guthrie R.

Adv Ther. 2011 Jun;28(6):473-82. doi: 10.1007/s12325-011-0026-0. Epub 2011 May 3. Review.

PMID:
21547541
14.

What's new in stroke? The top 10 studies of 2006-2008. Part I.

Hart RG.

Pol Arch Med Wewn. 2008 Nov;118(11):650-7. Review.

15.

Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.

Skliut M, Jamieson DG.

Curr Cardiol Rep. 2008 Feb;10(1):9-16. Review.

PMID:
18416995
16.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

17.

Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.

Weimar C, Cotton D, Sha N, Sacco RL, Bath PM, Weber R, Diener HC.

Cerebrovasc Dis. 2013;35(6):538-43. doi: 10.1159/000351144. Epub 2013 Jun 25.

PMID:
23816610
18.

Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.

Simmons BB, Yeo A, Fung K; American Heart Association; American Stroke Association.

Postgrad Med. 2010 Mar;122(2):49-53. doi: 10.3810/pgm.2010.03.2121. Review.

PMID:
20203455
19.

Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?

Diener HC.

Int J Stroke. 2006 Feb;1(1):4-8. doi: 10.1111/j.1747-4949.2005.00016.x.

PMID:
18706062
20.

Evolving perspectives on clopidogrel in the treatment of ischemic stroke.

Gorelick P, Sechenova O, Hennekens CH.

J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):245-8. Review.

PMID:
17220470
Items per page

Supplemental Content

Write to the Help Desk